bioavailability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
== Antibody vulnerability period in children == The period following birth is critical for the development of a child's immune system. Initially, a newborn relies heavily on passive immunity transferred from the mother, primarily through the placenta and breastfeeding. As breastfeeding frequency declines, immune protection gradually wanes, making the child more vulnerable and increasingly reliant on their developing immune system. This transitional phase, known as the "antibody vulnerability period", lasts until approximately three to four years of age, during which the child's immune system matures and becomes fully functional. To combat pathogens, babies need to develop their own specific antibodies recognizing these antigens. And these types of antibodies are known as immunoglobulins. Immunoglobulin G (IgG) is one of them. Babies are unable to make their own IgG antibodies at birth and rely on maternal transfer of IgG via the placenta during the third trimester. Other types of immunoglobulins (IgA, IgM, IgE, and IgD) do not cross the placenta. It is believed that IgG is important in protecting babies against infections. Naturally bioactive Immunoglobulin G is found in breast milk, which plays a significant role in early life during the vulnerable period. The Y-shaped structure of Immunoglobulin G allows it to effectively identify and combat pathogens, providing antibody-like protection to the child. Research indicates that maintaining adequate IgG levels during early childhood may help mitigate the risks associated with this immune vulnerability.
=== Reactant recycling === Because the urea conversion is incomplete, the urea must be separated from the unconverted reactants, including the ammonium carbamate. Various commercial urea processes are characterized by the conditions under which urea forms and the way that unconverted reactants are further processed.
== Selected bibliography == Daly, Marie M.; Mirsky, A.E. (June 1949). "Chromatography of Purines and Pyrimidines on Starch Columns". Journal of Biological Chemistry. 179 (2): 981–982. doi:10.1016/S0021-9258(19)51291-1. PMID 18150028. Daly, M.M.; Allfrey, V.G.; Mirsky, A.E. (May 20, 1950). "Purine and Pyrimidine Contents of Some Desoxypentose Nucleic Acids" (PDF). Journal of General Physiology. 33 (5): 497–510. doi:10.1085/jgp.33.5.497. PMC 2147206. PMID 15422104. Daly, Marie; Mirsky, A.E.; Ris, Hans (March 20, 1951). "The Amino Acid Composition and Some Properties of Histones" (PDF). The Journal of General Physiology. 34 (4): 439–450. doi:10.1085/jgp.34.4.439. PMC 2147226. PMID 14824510. Daly, Marie M.; Mirsky, A.E. (November 1952). "Formation of Protein in the Pancreas". Journal of General Physiology. 36 (2): 243–254. doi:10.1085/jgp.36.2.243. PMC 2147369. PMID 13011280. Daly, Marie M.; Allfrey, V.G.; Mirsky, A.E. (November 1952). "Uptake of Glycine-N15 by Components of Cell Nuclei" (PDF). Journal of General Physiology. 36 (2): 173–179. doi:10.1085/jgp.36.2.173. PMC 2147362. PMID 13011275. Allfrey, V.; Daly, M.M.; Mirsky, A.E. (November 20, 1953). "Synthesis of protein in the pancreas. II. The role of ribonucleoprotein in protein synthesis". Journal of General Physiology. 37 (2): 157–175. doi:10.1085/jgp.37.2.157. PMC 214743. PMID 13109153. Mirsky, A.E.; Allfrey, V.G.; Daly, M.M. (September 1954). "The Uptake of N15-Labelled Glycine by Liver Proteins". Journal of Histochemistry and Cytochemistry. 2 (5): 376–377. doi:10.1177/2.5.376. PMID 13192326. S2CID 40223958.
Sources: en.wikipedia.org
On 21 November 2024 the Federal Police indicted Bolsonaro and 36 other people related to Bolsonaro's defeat in the 2022 presidential elections. He is alleged to have known of a plot to assassinate his successor, Luiz Inácio Lula da Silva, and to overturn the election result. The trial against Bolsonaro and 80 other officials began in Brasília on 19 May 2025. On 9 July 2025 US president Donald Trump criticized the criminal prosecution of Bolsonaro, accused Brazil of being an unfair trading partner, and claimed the 50% tariff imposition was still less than what the US needed for a "level playing field"—despite the US trade surplus with Brazil. This led to comparisons about federal prosecution of Donald Trump involving the scandal with Stormy Daniels and Lula's arrest, and Trump's eligibility after the 6 January United States Capitol attack versus Bolsonaro's ineligibility after the 8 January Brasília attacks. Bolsonaro could request US political asylum—especially given that Trump labelled Brazil's charges a "witch hunt"—but would need safe‑conduct to leave Brazil and must prove credible political persecution. US authorities would then decide whether to grant asylum; diplomatic tensions and travel restrictions would make the outcome uncertain. On 18 July 2025 police again searched his home and ordered him to wear an electronic ankle tag. On 26 August he was placed under 24-hour surveillance after being designated as a "flight-risk".
Team Fortress Classic received positive reviews, garnering a rating of 85% on the video game review aggregator site GameRankings. PC Gamer US named Team Fortress Classic the best multiplayer game of 1999, and wrote that it was "more fun and more addictive than any other multiplayer-only title released in 1999, and didn't cost owners of Half-Life a single penny". PC Gamer UK praised the multiple character classes, "sophisticated game-tactics", and drive to work together with your team, but criticized the "clunky" team communication and graphics. Graham Smith of Rock, Paper, Shotgun criticized it as "messy" and "chaotic". In 2010, it was included in the book 1001 Video Games You Must Play Before You Die. As of February 2001, Team Fortress had sold 2.5 million copies.
Troglitazone was developed by Daiichi Sankyo (Japan). In the United States, it was introduced and manufactured by Parke-Davis in the late 1990s but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. The Food and Drug Administration (FDA) medical officer assigned to evaluate troglitazone, John Gueriguian, did not recommend its approval due to potentially high liver toxicity; Parke-Davis complained to the FDA, and Gueriguian was subsequently removed from his post. A panel of experts approved it in January 1997. Once the prevalence of adverse liver effects became known, troglitazone was withdrawn from the British market in December 1997, from the United States market in 2000, and from the Japanese market soon afterwards. It did not get approval in the rest of Europe. Troglitazone was developed as the first anti-diabetic drug having a mechanism of action involving a decrease in insulin resistance. At the time, it was widely believed that such drugs, by addressing the primary metabolic defect associated with Type 2 diabetes, would have numerous benefits including avoiding the risk of hypoglycemia associated with insulin and earlier oral antidiabetic drugs. It was further believed that reducing insulin resistance would potentially reduce the very high rate of cardiovascular disease that is associated with diabetes. Parke-Davis/Warner Lambert submitted the diabetes drug Rezulin for FDA review on July 31, 1996. The medical officer assigned to the review, Dr. John L.
According to Illarionov, Russian authorities had been preparing for the war for nearly a decade and "By supplying South Ossetia with heavy military equipment in February 2003, [...] the Russian government deliberately chose a military solution to the conflict with Georgia." Illarionov noted that "Mostly the Russian-Abkhaz-South Ossetian coalition in most cases made the first moves, to which the Georgians responded." He also noted that on 2 August 2008, the Russian journalists started to arrive in Tskhinvali who were ready to report on a war that had not yet begun and their number rose to 50 by 7 August. In July 2009, the Moscow Defence Brief, a magazine published by CAST, pointed out that:
Sources: en.wikipedia.org
=== Biosynthesis === Dipeptides are produced from polypeptides by the action of the hydrolase enzyme dipeptidyl peptidase. Dietary proteins are digested to dipeptides and amino acids, and the dipeptides are absorbed more rapidly than the amino acids, because their uptake involves a separate mechanism. Dipeptides activate G-cells found in the stomach to secrete gastrin.
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression. It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics. As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder. In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial. Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.
It has also been suggested that elective surgery recipients should be prioritized since a patient recovering from surgery would be more vulnerable than average. Some expressed concern over the short shelf-life of the Moderna and Pfizer-BioNTech vaccines, which expire within hours after being removed from the freezer; they argued that, once the vaccine is unfrozen, it is better to apply these doses to anyone who can be found rather than discard the doses. As of March 2021, the United States had ordered twice the necessary doses to cover its own population, but it remained unclear when it might share surplus doses with other countries. In April 2021, Vanity Fair reported that it would be difficult to share surplus doses with other countries because the U.S. government had expressly agreed in its contracts with vaccine manufacturers to use doses only in the United States and its territories. The manufacturers requested this clause because most other countries do not have liability protections for vaccines as expansive as the Public Readiness and Emergency Preparedness Act. In late November 2021 the World Health Organization published, "it is vitally important that inequities in access to COVID-19 vaccines are urgently addressed to ensure that vulnerable groups everywhere, including health workers and older persons, receive their first and second doses, alongside equitable access to treatment and diagnostics." Inequalities in vaccine distribution facilitate the emergence of new variants like SARS-CoV-2 Omicron variant.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.